Complete eradication of chronic lymphocytic leukemia with unusual skin involvement of high mitotic index after time ‐limited venetoclax/obinutuzumab treatment

The novel time-limited combinations with the bcl-2 inhibitor venetoclax can induce deep responses even in CLL cases with unusual and biologically aggressive presentations, like the skin masses of our patient. AbstractThe novel time-limited combinations with the bcl-2 inhibitor venetoclax can induce deep responses even in CLL cases with unusual and biologically aggressive presentations, like the skin masses of our patient.

Source: Clinical Case Reports - July 23, 2021 Category: General Medicine Authors: Maria Dimou, Theodoros Iliakis, Vasileios Paradalis, Aikaterini Bitsani, Marie ‐Christine Kyrtsonis, Panayiotis Panayiotidis Tags: CLINICAL IMAGE Source Type: research